NEC Bio to Present Early Results for Oral Neoantigen Therapy

NEC Bio, a division of NEC Corporation, is set to present early-stage results for its oral neoantigen therapy, emphasizing its focus on personalized cancer immunotherapies. This presentation represents a key milestone in the clinical evaluation of their proprietary technology. The company is utilizing its expertise in AI and data analysis to further its medical research initiatives.